<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00553215</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000574081</org_study_id>
    <secondary_id>CRUK-BCPP-2005-01-QOL</secondary_id>
    <secondary_id>ISRCTN13889738</secondary_id>
    <secondary_id>EU-20768</secondary_id>
    <nct_id>NCT00553215</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients With Bladder Cancer</brief_title>
  <official_title>Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [QOL]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying quality of life in patients with bladder cancer may help determine the&#xD;
      long-term effects of bladder cancer and may help improve the quality of life for patients in&#xD;
      the future.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying quality of life in patients with bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To study the effects of recurrence and progression on health-related quality of life&#xD;
           (HRQL).&#xD;
&#xD;
        -  To study the effects of repeat cystoscopy on HRQL.&#xD;
&#xD;
        -  To study the patients' assessments of a hypothetical prognostic model and how this&#xD;
           affects their preference for the mode of surveillance.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Quality-of-life questionnaires developed by the European Organization for Research and&#xD;
      Treatment for Cancer (EORTC) will be used. The EORTC QLQ-BLS24 with 24 questions specific to&#xD;
      non-muscle-invasive bladder cancer and the EORTC QLQ-BLM30 with 30 questions specific to&#xD;
      muscle-invasive bladder cancer will be combined and used in conjunction with the general&#xD;
      cancer questionnaire QLQ-C30.&#xD;
&#xD;
      Assessments using the QLQ-C30 will be made at baseline in the entire cohort of patients.&#xD;
      Follow-up assessments using the QLQ-C30, QLQ-BLS24, and QLQ-BLM30 167 will be made at first&#xD;
      routine follow-up and annually until the end of study.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Quality of life as measured by EORTC QLQ-C30, QLQ-BLS24, and QLQ-BLM30 questionnaires</measure>
  </primary_outcome>
  <enrollment>2700</enrollment>
  <condition>Bladder Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Enrolled on parent protocol CRUK-BCPP-2005-01&#xD;
&#xD;
          -  Bladder lesion with cystoscopic characteristics compatible with urothelial cancer or&#xD;
             transitional cell carcinoma meeting 1 of the following criteria:&#xD;
&#xD;
               -  Non-muscle-invasive tumor&#xD;
&#xD;
               -  Muscle-invasive tumor&#xD;
&#xD;
               -  Solitary G1 pTa tumor&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Previous diagnosis of cancer of the urethra, bladder, ureter, or renal pelvis within&#xD;
             the 10 years prior to current diagnosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Fit for cystoscopy and surgical biopsy/resection&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Any condition that, in the opinion of the local investigator, might interfere with the&#xD;
             safety of the patient or evaluation of the study objectives&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Zeegers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Zeegers, MD</last_name>
      <phone>44-121-414-6721</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>November 2, 2007</study_first_submitted>
  <study_first_submitted_qc>November 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2007</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>stage 0 bladder cancer</keyword>
  <keyword>stage I bladder cancer</keyword>
  <keyword>stage II bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

